The portal for rare diseases and orphan drugs
- 1*
- 1Department of Pharmacology, Government Medical College, Amritsar, India.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: Jatinder Singh
Department of Pharmacology, Government Medical College, Amritsar, India.
Email: singh@gmc.edu.in
Copyright: © 2013 The Author(s). This is an open access article.
Published: Jan 1, 2013
- DOI
- Not available yet
Abstract
Orphan drugs are the stepchildren of the pharmaceutical industry. These medicinal products that are used primarily for the prevention or treatment of life‑threatening or debilitating rare diseases have restricted markets and thus limited profitability. As a consequence, the pharmaceutical industry has little interest in developing and marketing these drugs which are intended for patients who suffer from rare conditions.
Keywords
Subject
Recommended articles
- International conference on harmonization of technical requirements for registration of pharmaceuticals for human use
Jatinder Singh · Journal of Pharmacology and Pharmacotherapeutics
- Randomization and online databases for clinical trials
Jatinder Singh · Journal of Pharmacology and Pharmacotherapeutics
- Mini Manuscript
Jatinder Singh · Journal of Pharmacology and Pharmacotherapeutics
- The pharmacovigilance toolkit
P. Ravi Shankar · Journal of Pharmacology and Pharmacotherapeutics
- Guide to Pharmacology
Jatinder Singh · Journal of Pharmacology and Pharmacotherapeutics
- Protein data bank
S. Parasuraman · Journal of Pharmacology and Pharmacotherapeutics
Readers Also Viewed
Clinical Outcomes and Management of Post-varicocelectomy on Male Fertility: A Comprehensive Review
Mohammad Akbar Hossain
Jan 1, 2026
Exploring Interleukin-6 Inhibitor Antibodies in Combatting SARS-CoV-2 and its Mutated Variants: Challenges and Future Directions
Mohammed Ali Bakkari, Gassem Ghoal, Fahad Y. Sabei
Jan 1, 2025
Pharmacogenomics Meets Generative AI: Transforming Clinical Trial Design with Large Language Models
Annisa Fatharani, Ali Alsayegh
Jan 1, 2026